COMMUNIQUÉS West-GlobeNewswire

Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology
11/05/2026
NORCROSS, Ga., May 11, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), a clinical-stage biotechnology company developing therapeutics that target galectin-3 for patients with MASH cirrhosis and portal [...]
Jabez Biosciences Presents First-in-Human Pharmacokinetic and Pharmacodynamic Data for JBZ-001 at AACR Annual Meeting 2026
11/05/2026
Phase 1 Clinical Data Demonstrate Dose-Proportional PK, No Dose-Limiting Toxicities Through Four Dose Levels, and Concordance with Preclinical PBPK Predictions CRANBERRY TOWNSHIP, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- [...]
First Participant Dosed in AskBio Phase 1/Phase 2 Gene Therapy Trial of AB-1009 for Late-Onset Pompe Disease (LOPD)
11/05/2026
Durham, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- AB-1009, an adeno-associated virus (AAV) investigational gene therapy, is being evaluated for the treatment of late-onset Pompe disease (LOPD) in the PROGRESS-GT LOPD trial [...]
CPTx appoints Edward Rebar as Chief Scientific Officer
11/05/2026
Rebar will focus on establishing a pipeline of in vivo CAR T therapeutic programs based on the company’s proprietary immune-quiet DNA vector platform David Maier appointed to expanded role as CPTx Chief Business Officer [...]
ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform
11/05/2026
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies [...]
Sironax’s SARM1 Inhibitor SIR2501 Granted FDA Fast Track Designation in Chemotherapy-induced Peripheral Neuropathy (CIPN)
11/05/2026
CIPN is a common nerve-damaging side effect of chemotherapy with no FDA-approved treatment options Fast Track designation reflects the significant unmet need and enables potential accelerated drug development WALTHAM, [...]
Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial
11/05/2026
Registration Now Open - Join the Live Webinar on June 10, 2026 Vancouver, Canada, May 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“ Clearmind ” or the “ Company ” ), a clinical-stage biotech [...]
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
11/05/2026
Presented positive Phase 3 HAELO topline clinical data for lonvo-z in HAE; initiated rolling BLA submission; anticipate U.S. launch in first half of 2027 Recently resumed patient screening in MAGNITUDE and MAGNITUDE-2 [...]
Cronos Group Reports 2026 First Quarter Results
11/05/2026
Net revenue in Q1 2026 increased by 40% year-over-year to $45.2 million Achieved record net revenue and gross profit in Q1 2026 Reached #1 market share in vapes in Canada 1 Ninth consecutive quarter of record net [...]
The Future of Intoxication Detection May Be in Your Voice
11/05/2026
AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage : The ability to accurately detect drug and alcohol intoxication has long been a persistent challenge across industries, from law enforcement [...]
Alvotech announces completion of FDA surveillance inspection at Reykjavik facility
11/05/2026
Company remains on track for BLA resubmissions in the second quarter REYKJAVIK, ICELAND – May 11, 2026 – Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture [...]
Certara Reports First Quarter 2026 Financial Results
11/05/2026
Updates 2026 Guidance to reflect completed divestiture of Regulatory Writing and Medical Writing Business RADNOR, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed [...]
Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility
11/05/2026
- Company remains on track for BLA resubmissions in the second quarter REYKJAVIK, Iceland, May 11, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the [...]
ENA Respiratory Successfully Completes First Part of Phase II Study of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
11/05/2026
MELBOURNE, Australia, May 11, 2026 (GLOBE NEWSWIRE) -- ENA Respiratory , a clinical-stage pharmaceutical company developing antiviral host defence enhancers to minimize the impact of symptomatic viral respiratory [...]
Anaveon Announces Presentation of Positive ANV600 Clinical Data at ASCO 2026 and Actively Seeks Partners for its Legacy Oncology Portfolio
11/05/2026
BASEL, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage preclinical biotechnology company focused on reprogramming the immune system for the treatment of autoimmune and inflammatory diseases, today [...]
Positive Results from PulseSight’s Phase I Clinical Trial of PST-611 in Dry AMD/Geographic Atrophy Presented at ARVO 2026
11/05/2026
PARIS, May 11, 2026 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive non-viral vectorized gene therapies with minimally-invasive delivery technology [...]
Bavarian Nordic – Completion of Share Buy-Back Program
11/05/2026
COPENHAGEN, Denmark, May 11, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on March 12, 2026, has now been completed, reaching an aggregate amount of [...]
Nxera Pharma Announces Progress of Out-Licensing of GPCR-targeted Program and Participation in Series A Financing
11/05/2026
New company (“NewCo”) co-founded by Nxera with a syndicate of leading healthcare and life sciences-focused investment firms. In return for granting an exclusive worldwide license to the program, Nxera is eligible to [...]
Leo International Precision Health AG: Planned nine acquisitions in Asia and Europe for inorganic growth
11/05/2026
Leo International Precision Health AG / Keyword: Mergers and Acquisitions / Purchase of parts of a company Leo International Precision Health AG: Planned nine acquisitions in Asia and Europe for inorganic growth 11. May [...]

Pages